Pseudomyxoma peritonei syndrome.
Sugarbaker
P H
PH
Washington Cancer Institute, Washington, DC, USA.
Ronnett
B M
BM
Archer
A
A
Averbach
A M
AM
Bland
R
R
Chang
D
D
Dalton
R R
RR
Ettinghausen
S E
SE
Jacquet
P
P
Jelinek
J
J
Koslowe
P
P
Kurman
R J
RJ
Shmookler
B
B
Stephens
A D
AD
Steves
M A
MA
Stuart
O A
OA
White
S
S
Zahn
C M
CM
Zoetmulder
F A
FA
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D011553:Pseudomyxoma Peritonei / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil